Another ASO in development is aimed at altering the metabolic state of liver cancer cells by altering the balance between pyruvate kinase isoforms encoded by splice variants of the M2 pyruvate kinase gene (PKM), which is highly expressed in most cancers (Reviewed by Peng et al. [34]). This evidence concerns the gene PKM and cancer.